Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma

Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Sep 9, 2021

Keywords

ClinConnect Summary

This study is design to prospectively investigate the safety and efficacy of 68Ga-DOTA-NT-20.3 in the early diagnosis of pancreatic ductal adenocarcinoma (PDAC). The specific objectives are the determination of pharmacokinetics, dosimetry, tolerance and tumor detection rate of 68Ga-DOTA-NT-20.3 in patient with PDAC. Neurotensin receptor 1 (NTR-1) is the high affinity receptor of Neurotensin (NT), which was found abnormal expression in the early stages of PDAC malignant cell transformation. 68Ga-DOTA-NT-20.3 as a new NTR-1 targeted probe was prepared and showed good uptake on PDAC cell line ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patient with pathohistologically proven localized or metastatic PDAC;
• • patient aged 18 or older, male or female, who can provide written informed consent for this study;
• • patient with complete clinical data.
• Exclusion Criteria:
• • patient age \< 18 years;
• • patient with other active cancer;
• • patient with PDAC under the treatment blocking NT receptors;
• • pregnant or lactating women;
• • patient who cannot stay on PET/CT camera for app. 90 minutes;
• • patient who cannot stand MRI;
• • patient simultaneously participating in another clinical trial;
• • patient with HIV, HCV, HVB infection or other serious chronic infection
• • patient with serious mental, neurological, cardiovascular, respiratory and other system diseases;
• • patient with liver and kidney function (GFR less than 50 ml/min) disease;
• • patient with severe severe refractory mental disorder.